|OncoCyte Corporation to Present at the BIO CEO Investor Forum|
October 17, 2018
|ALAMEDA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, President and Chief Executive Officer, will provide a corporate overview at the BIO Investor Forum, being held October 17-18, 2018 in San Francisco, California.
OncoCyte Corporation Presentation Details:
Thursday, October 18
|Asterias Biotherapeutics Announces Facilities and IP License Option Agreements|
October 01, 2018
|Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed Overhead
FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced it has entered into two new agreements with an affiliate of Novo Nordisk, a ... |
|BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences|
September 27, 2018
|ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 27, 2018--
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that Russell
Skibsted, Chief Financial Officer, will present at the upcoming MicroCap
and Ladenburg Thalmann conferences.
The MicroCap Conference will take place on October 1, 2018 at the
Essex House in New York. The presentation will take place at 10:30am
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|